Sen. Cassidy said that Kennedy made a number of promises to the Senate nomination committee, which he's now breaking, including not changing the ACIP, a highly influential panel that makes vaccine recommendations & shapes the childhood vaccination schedule nbcnews.com/health/health-…

New in Journal of Clinical Oncology proof of-concept phase II trial shows lean body mass–based oxaliplatin dosing in stage III colon cancer reduces neurotoxicity vs. standard BSA-based dosing, with no DFS compromise. #GIonc #CRC #OncoResearch ascopubs.org/doi/10.1200/JC…

Nice review & algorithm for systemic management of Stage IV gastric/GEJ cancers! Also great pts re: zolbetuximab - GLOW/SPOTLIGHT positive trials, but ~2 month PFS/OS improvement should be weighed against high toxicity (Grade 3+ ~80%) which could def worsen QOL.

Following trastuzumab deruxtecan approval, HER2 IHC 3+ testing across 65,000 solid tumors demonstrates varied prevalence. ja.ma/4elKj10

Walking to show solidarity for those affected by #colorectalcancer. We support you! Thanks to Colorectal Cancer Alliance for organizing this important event every year! CU Cancer Center uchealth

FORTITUDE 101 is a positive Phase 3 study in FGFR2b overexpresssed gastroesophageal cancers! Looking forward to seeing the data and also for FORTITUDE 102 results with combines IO. #FGFR2b amgen.com/newsroom/press….

Excited to have CU Cancer Center be a part of this effort to investigate a CLDN18.2 4-!BB bispecific Ab for gastroesophageal cancer.

Revolution Medicines Announces FDA Breakthrough Therapy Designation for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer with KRAS G12 Mutations | Revolution Medicines #ESMOGI25 ir.revmed.com/news-releases/…

Our meta-analysis (n=12,698) shows: Omitting 5-FU bolus from GI chemo regimens → ✔️ No difference in PFS/OS 📉 Less grade 3–4 neutropenia (OR 0.46) 📉 Less thrombocytopenia (OR 0.53) YUSUF İLHAN Yakup Ergün OncoDaily OncoAlert LARVOL

This needs to get much more attention! FDA should provide an indication or NCCN list it as an intervention so insurance will pay for exercise programs in patient with cancer! That’s what would happen if this was some “expensive-atinib”!! nejm.org/doi/full/10.10…

The future is bright!!

.Benjamin Weinberg, MD, FACP presents the EXPEL PANC trial: 2nd line pembro + BXCL701 in metastatic #pancreaticcancer: 17% response rate, 39% disease control rate, PFS 2.3 months, OS not reached, 3 patients progression free > 6 months, hope on the horizon for #immunotherapy in panc

My lab’s 5-year NIH R01 grant, awarded to study gene therapy for hearing loss, was abruptly terminated. I want to share how this action has been incredibly harmful and disruptive, not just to my lab, but to the scientific process itself. 1/15

Why is it so hard for people, especially some wellness influencers, to admit this simple truth…. You can do everything right. You can eat the kale, take the supplements, walk 10k steps a day, lift the weights, meditate, sleep 8 hours, avoid sugar, avoid seed oils, avoid

Every time a radiologist marks key images on an MRI an angel gets its wings

Phase 1b of BL-B01D1 (EGFRxHER3 TOPO1i BsADC) in esophageal squamous cell carcinoma published on Nature Medicine 2.5 mg/kg D1D8 Q3W, ORR=40% (21/53) 2.0 mg/kg D1D8 Q3W, ORR=15% (3/20) No significant correlation between response and expression of EGFR, HER3, or both (small #).

☢️Adjuvant (chemoradiation plus immunotherapy) vs (observation) for eCCA and Gallbladder Cancer ACCORD JAMA Oncology ➡️2xcamrelizumab, CRT ( 2x1330mg/m2 capecitabine, up to 55gy in 25fx), camrelizumab until progression/toxicity ✅OS HR: 0.43 (0.24-0.79) P = .004 ✅RFS HR: 0.46

👉 The treatment landscape for #gastroesophageal cancers has shifted since immunotherapy and molecular profiling have become available. ⭐ We recently spoke with Drs. Suneel Kamath MD and Sunnie Kim, MD about this rapidly changing landscape in upper GI cancers: buff.ly/hXjEOGq

And back to back publication of IBI343, another CLDN18.2 TOPO1i ADC. In this case, exatecan payload using Synaffix technology. Better response rates in moderate to high CLDN18.2 expression vs moderate. And overall better safety at 6.0 mg/kg Q3W (dose chosen for ongoing phase 3)

Happy to share initial report on temporal change of CLDN18.2 after chemo + zolbetuximab: ~50% showed decreased expression (<75%+ cells) on PD, but 75% retained ≥25% expression—supporting potential for other CLDN-targeted tx like ADCs ESMO Open ESMO - Eur. Oncology   sciencedirect.com/science/articl…